#weightloss
weightloss
24 views
2 Discussing
Hot
Latest
🚨 $LLY INSTITUTIONAL POSITIONING FOR THE NEXT WEIGHT LOSS BLOCKBUSTER 🚀💊
📊 Eli Lilly just confirmed plans to file for Retatrutide approval by Q1 2027 — a timeline shift that still sparked a 2% rally. 🦈 Smart money interprets this as a deliberate pace to perfect manufacturing quality before flooding the market.
💡 Phase 3 data is exceptional: 20.8% weight loss in obese diabetics and 22.6% in those with cardiovascular conditions — all via a triple-hormone mechanism (GLP-1 + GIP + glucagon). That’s a structural leap beyond current GLP-1 treatments. 📌 With 20/22 analysts rating it a Buy and a median price target of $1,294, the risk-reward remains institutionally rotated.
💬 Will Retatrutide help $LLY maintain its edge over Novo Nordisk in the global GLP-1 race, or is competition heating up more than expected? 👇
⚠️ Not financial advice. Always manage your risk. 🛡️
🏷️ #LLY #WeightLoss #Pharma #Biotech #GrowthStock
🚀 💎
📊 Eli Lilly just confirmed plans to file for Retatrutide approval by Q1 2027 — a timeline shift that still sparked a 2% rally. 🦈 Smart money interprets this as a deliberate pace to perfect manufacturing quality before flooding the market.
💡 Phase 3 data is exceptional: 20.8% weight loss in obese diabetics and 22.6% in those with cardiovascular conditions — all via a triple-hormone mechanism (GLP-1 + GIP + glucagon). That’s a structural leap beyond current GLP-1 treatments. 📌 With 20/22 analysts rating it a Buy and a median price target of $1,294, the risk-reward remains institutionally rotated.
💬 Will Retatrutide help $LLY maintain its edge over Novo Nordisk in the global GLP-1 race, or is competition heating up more than expected? 👇
⚠️ Not financial advice. Always manage your risk. 🛡️
🏷️ #LLY #WeightLoss #Pharma #Biotech #GrowthStock
🚀 💎
Log in to explore more content